Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

Smith et al., NCT04358068, NCT04358068

Jul 2020

Source PDF All Studies Meta AnalysisMeta

Early terminated NIAID RCT for HCQ. Patients >60 were only in the HCQ arm. 57% of patients were high risk in the HCQ arm vs. 22% for control. Treatment started up to 20 days after symptoms.

Important missing comments or errors? Let us know.

risk of hospitalization, 64.0% lower, RR 0.36, p = 1.00, treatment 0 of 7 (0.0%), control 1 of 9 (11.1%), NNT 9.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).

recovery time, 10.0% higher, relative time 1.10, treatment 7, control 9.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Smith et al., 8 Jul 2020, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04358068 (history).

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0